MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2022.06.041

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2022

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

Larkin James, Weber Jeffrey, Del Vecchio Michele, Gogas Helen, Arance Ana M, Dalle Stephane, Cowey C Lance, Schenker Michael, Grob Jean-Jacques, Chiarion-Sileni Vanna, Márquez-Rodas Iván, Butler Marcus O, Di Giacomo Anna Marie, Middleton Mark R, De la Cruz-Merino Luis, Arenberger Petr, Atkinson Victoria, Hill Andrew, Fecher Leslie A, Millward Michael, Khushalani Nikhil I, Queirolo Paola, Long Georgina V, Lobo Maurice, Askelson Margarita, Ascierto Paolo A, Mandalá Mario

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8.

PATIENTS AND

METHODS

In a double-blind, phase 3 trial (NCT02388906), patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were randomised to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year. Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were assessed in patients with stage III disease, per AJCC-7 and AJCC-8.

RESULTS

Per AJCC-7 staging, 42.4% and 57.3% of patients were in substage IIIB and IIIC, respectively; per AJCC-8, 1.1%, 30.4%, 62.8%, and 5.0% were in IIIA, IIIB, IIIC, and IIID. After 4 years' minimum follow-up, the AJCC-7 superior efficacy of nivolumab over ipilimumab in patients with resected stage III melanoma was preserved per AJCC-8 analysis. No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for DMFS).

CONCLUSIONS

CheckMate 238 4-year RFS and DMFS outcomes are consistent per AJCC-7 and AJCC-8 staging criteria. Outcome benefits can therefore be translated for patients diagnosed per AJCC-8.

Для цитирования: Larkin James, Weber Jeffrey, Del Vecchio Michele, Gogas Helen, Arance Ana M, Dalle Stephane, Cowey C Lance, Schenker Michael, Grob Jean-Jacques, Chiarion-Sileni Vanna, Márquez-Rodas Iván, Butler Marcus O, Di Giacomo Anna Marie, Middleton Mark R, De la Cruz-Merino Luis, Arenberger Petr, Atkinson Victoria, Hill Andrew, Fecher Leslie A, Millward Michael, Khushalani Nikhil I, Queirolo Paola, Long Georgina V, Lobo Maurice, Askelson Margarita, Ascierto Paolo A, Mandalá Mario. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.. European journal of cancer (Oxford, England : 1990). 2022. DOI: 10.1016/j.ejca.2022.06.041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.